Founding investor Mercia Technologies joined fund manager Invesco for the synthetic biology contractor’s latest round, taking its total funding past the $25m mark.

Oxford Genetics, a UK-based synthetic biology services provider founded by a former University of Oxford scientist, has secured £6.5m ($8.5m) in funding at a post-money valuation of approximately $40m. The round included Mercia Technologies, the research-focused investment firm Mercia Technologies that is also Oxford Genetics’ founding investor, as well as fund manager Invesco Asset Management…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.